Good
Mostly Aligned
Patient Risk:
Low
Summary
The statements broadly and correctly frame that the provided Cosentyx label excerpts do not indicate PSA-based dosing adjustments, and emphasize dosing determined by indication/weight-based regimens and required pre-treatment evaluations (e.g., TB, vaccinations). However, the response includes generalizations about “age category” and “clinicians generally focus” that are not directly supported by the provided label excerpts, and it does not explicitly account for any label-specific dosing nuances beyond “every 4 weeks thereafter” (and HS possible increase).
Category Scores
Accurate Statements
Cosentyx dosing is not adjusted based on a patient's PSA (prostate-specific antigen) level.
Supported indirectly by the absence of any PSA-related dosing parameter in the provided label excerpts; dosing sections provided specify regimens by indication and timing (e.g., plaque psoriasis 300 mg at Weeks 0–4 then every 4 weeks; HS option to increase to every 2 weeks if inadequate response) and pre-treatment evaluations include TB and vaccinations rather than PSA. (Sections 2.1, 2.3, 2.10)
PSA is a lab marker used for prostate evaluation (e.g., screening and follow-up in prostate health).
Not addressed in the provided label excerpts; however, this statement does not conflict with the label.
Cosentyx dosing schedules are based on the specific condition being treated (e.g., plaque psoriasis or psoriatic arthritis) and the patient's age category, not prostate lab values.
Condition-based dosing is supported (e.g., different indication sections with specific regimens such as plaque psoriasis and HS). Age-based dosing/suitability is supported for pediatric indications (Sections 1 and 8.4), but the precise statement that schedules are based on an “age category” is not directly evidenced in the provided dosing excerpts.
Unsupported Statements
Cosentyx dosing for psoriasis/psoriatic arthritis does not reference PSA in the available prescribing information dosing approach.
The label excerpts show dosing regimens by indication and timing but do not explicitly mention PSA; there is no explicit label statement confirming “does not reference PSA.” This is best supported as an absence-of-evidence rather than a direct support.
Clinicians generally focus on disease-specific response and safety monitoring relevant to Cosentyx, such as infection risk and other lab/safety considerations tied to the underlying condition and comorbidities.
The label excerpts include warnings/precautions and pre-treatment evaluations (e.g., TB, vaccinations, infections/IBD/hypersensitivity), but they do not support the generalization about “clinicians generally focus” on particular monitoring priorities.
Cosentyx dosing schedules are based on ... the patient's age category, not prostate lab values.
The excerpts support age-qualified indications and pediatric administration rules, but the provided dosing regimen excerpts (e.g., 300 mg schedules) do not describe dose changes by age category for adult dosing.
PSA testing may be relevant for other reasons ... but it is not used as a dose-adjustment parameter for Cosentyx.
The label excerpts do not discuss PSA testing or its clinical role; the “not used as a dose-adjustment parameter” part is supported only indirectly by absence of PSA in dosing/pre-treatment evaluation sections.
Contradictions
Important Omissions
No discussion of label-specified pre-treatment evaluations and key safety precautions (TB testing/avoid active TB, vaccination guidance including avoiding live vaccines, and specific boxed-warning-like major risks if present in the full label) beyond infection risk generally.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The core theme (no PSA-based dosing adjustment) is consistent with the provided label excerpts. Remaining issues are mainly unsupported generalizations and indirect reliance on absence-of-mention rather than direct label confirmation.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Some statements are generalized (“clinicians generally focus…”, “age category” driving dosing) or rely on absence-of-mention rather than direct label support.
Suggested Improvement
Tighten claims to what the provided label excerpts show explicitly: dosing regimens specified by indication/timing and pre-treatment evaluations (TB, vaccinations) rather than PSA; avoid general clinician-behavior statements and avoid stating age categories affect dosing schedules unless directly supported by the provided dosing sections.